Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?

被引:12
|
作者
Pinelli, Valentina [1 ]
Roca, Elisa [3 ]
Lucchini, Silvia [2 ]
Laroumagne, Sophie [3 ]
Loundou, Anderson [4 ]
Dutau, Herve [3 ]
Maldonado, Fabien [6 ]
Astoul, Philippe [3 ,5 ]
机构
[1] Hosp S Bartolomeo, Div Pneumol, Sarzana, Italy
[2] Spedali Civil Brescia, Div Nucl Med, I-25125 Brescia, Italy
[3] Hop Nord Marseille, Div Thorac Oncol Pleural Dis & Intervent Pulmonol, FR-13326 Marseille 20, France
[4] Aix Marseille Univ, Dept Publ Hlth & Biostat, Marseille, France
[5] Aix Marseille Univ, Fac Med, Marseille, France
[6] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA
关键词
Pleural mesothelioma; F-18-fluorodeoxyglucose-positron emission tomography; Thoracoscopy; Malignant pleural effusions; RESPONSE EVALUATION; CANCER-THERAPY; PET; MANAGEMENT; THORACOSCOPY; INADEQUACY; RESECTION; SURVIVAL; CRITERIA; DISEASE;
D O I
10.1159/000381922
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Careful clinical staging in patients with malignant pleural mesothelioma (MPM) is fundamental in management planning. Positron emission tomography/computed tomography (PET/CT) is increasingly recognized as an important staging modality. Objectives: The purpose of this study was to assess whether the metabolic activity of the pleural tumor detected with PET/CT correlates with specific endoscopic features and pleural distribution of the lesions as assessed by medical thoracoscopy. Methods: Consecutive patients with MPM and available PET/CT performed before thoracoscopy were separated into 2 groups, according to their standardized uptake value (SUV). Kaplan-Meier-analysis for survival was performed on groups with low and high SUV. Agreement between PET/CT and thoracoscopy evaluation was analyzed using Cohen's kappa coefficient. The Wilcoxon test was used to compare the median SUV, and the. 2 test was used to evaluate differences in endoscopic findings. Results: A total of 32 patients were included. The median maximum SUV (SUV max) was 6.1 and patients were separated into 2 groups based on this cutoff. Patients with SUV max < 6.1 had a better survival than those with SUV max >= 6.1 (p = 0.005). The comparison between PET/CT and thoracoscopy showed a fair agreement for visceral and diaphragmatic pleural involvement and moderate agreement for the presence of nodular lesions. There was a statistically significant association between median SUV max and visceral pleural involvement; nodular lesions and visceral pleural involvement were more common in the high-SUV group than in the low-SUV group (p = 0.0012 and p = 0.03, respectively). Conclusions: PET/CT data may be predictive of thoracoscopic features of MPM associated with prognosis and staging, but the correlation is moderate at best. A degree of disagreement exists between these two modalities, which supports thoracoscopy as the gold standard for assessment of local invasion in MPM. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:558 / 564
页数:7
相关论文
共 50 条
  • [41] Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma
    Ekanayake, Siyaguna K. D. M.
    Yang, Ian A.
    Godbolt, David B.
    Windsor, Morgan N.
    Henderson, Daniel
    Kyle, Samuel
    Sterling, David
    Lee, Joseph C.
    [J]. ANZ JOURNAL OF SURGERY, 2019, 89 (09) : E406 - E407
  • [42] The Staging of Malignant Pleural Mesothelioma
    Euhus, Caleb J.
    Ripley, R. Taylor
    [J]. THORACIC SURGERY CLINICS, 2020, 30 (04) : 425 - +
  • [43] Fluorodeoxyglucose versus Choline Positron Emission Tomography/Computed Tomography Response Evaluation in Two Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Neoadjuvant Chemotherapy
    Kitajima, Kazuhiro
    Nakamichi, Toru
    Hasegawa, Seiki
    Kuribayashi, Kozo
    Yamakado, Koichiro
    [J]. CUREUS, 2018, 10 (11):
  • [44] Efficacy of positron emission tomography and computed tomography in clinical staging of cutaneous malignant melanoma
    Yilmaz, Harun
    Orhan, Erkan
    Sahin, Ertan
    Olguner, Anil A.
    Arpaci, Enver
    [J]. DERMATOLOGIC THERAPY, 2020, 33 (03)
  • [45] The contribution of positron emission tomography in pleural disease
    Duysinx, B.
    Corhay, J. -L.
    Larock, M. -P.
    Withofs, N.
    Bury, T.
    Hustinx, R.
    Louis, R.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2008, 25 (02) : 129 - 138
  • [46] PROGNOSTIC VALUE OF STANDARD UPTAKE VALUE (SUV) OF 18F-FDG ASSESSED BY POSITRON EMISSION TOMOGRAPHY (PET) INTEGRATED WITH COMPUTED TOMOGRAPHY (CT) SCAN IN STAGING OF MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Genestreti, Giovenzio
    Moretti, Andrea
    Galassi, Riccardo
    Marzullo, Anna Maria
    Piciucchi, Sara
    Bersanelli, Melissa
    Tiseo, Marcello
    Dubini, Alessandra
    Matteucci, Federica
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1355 - S1356
  • [47] Cytology, chest computed and positron emission tomography correlations in lung cancer malignant pleural effusion.
    Brun, Clement
    Gay, Pierre
    Cottier, Michelle
    Karpathiou, Georgia
    Barral, Fabrice-Guy
    Vergnon, Jean-Michel
    Froudarakis, Marios E.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [48] Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma
    Tsutani, Y.
    Takuwa, T.
    Miyata, Y.
    Fukuoka, K.
    Hasegawa, S.
    Nakano, T.
    Okada, M.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (04) : 1005 - 1010
  • [49] Monitoring of chemotherapy response in multiple disseminated malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
    Kimura, T
    Kudoh, S
    Yoshimura, N
    Mitsuoka, S
    Matsuura, K
    Koyama, K
    Kawabe, J
    Okamura, M
    Hirata, K
    Shiomi, S
    Yoshikawa, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 664S - 664S
  • [50] Pleural Effusion Biomarkers And Computed Tomography Findings In Diagnosing Malignant Pleural Mesothelioma: A Retrospective Study In A Single Center
    Otoshi, T.
    Kataoka, Y.
    Ikegaki, S.
    Saito, E.
    Matsumoto, H.
    Kaku, S.
    Shimada, M.
    Hirabayashi, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195